LinkedIn · Feb 2026
A LinkedIn post highlighted Helen Chen speaking in a healthcare-track session and reiterated Alixia's precision-oncology focus.
Targeting the Tumor Ecosystem to address cancer drug resistance.
Company research
Public company, workplace, funding, and market signals
Overview
Alixia is a San Francisco biotech/precision-oncology startup developing tumor-ecosystem disruptors to combat cancer drug resistance by targeting the tumor microenvironment; public sources describe it as founder-led and research-heavy, with some disagreement on founding year (2018 vs. 2022).
Primary product
Tumor ecosystem disruptors for cancer drug resistance
Founded
2022
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncology therapeutics / precision oncology
Offices
953 Indiana Street, San Francisco, CA 94107
Business model
therapeutics development
drug discovery
biotechnology research
Funding
Stage
Seed
Total raised
$2.5M
Latest round
Seed · Jul 2024
Latest amount
$1.8M
People & investors
Work & culture
Mission-driven, research-intensive, and multidisciplinary, with scientists, clinicians, and drug developers collaborating on preclinical therapeutics.
Product & market
Differentiators
- —Targets the tumor ecosystem rather than a single mutation
- —Focuses on metabolic and inflammatory triggers in the tumor microenvironment
- —Uses an integrated biology/biophysics/computational chemistry/clinical-input platform
- —Aims to produce durable treatments for drug-resistant cancers
Technology
biology
biophysics
computational chemistry
clinical input
tumor microenvironment targeting
precision oncology
Competitors
Assertio
Courage Therapeutics
Celator Pharmaceuticals
Alnylam
Spark Therapeutics
Septerna
Scale & contact
Estimated revenue
USD 1M-$5M
Latest news
LinkedIn · Nov 2025
A LinkedIn post summarized a fireside conversation with the Alixia co-founders and described the company as a Y Combinator-backed biotech focused on drug resistance.
intelligence360 · Aug 2024
A secondary write-up on the SEC filing reported the exempt offering and framed it as funding to accelerate product development and company expansion.
SEC · Jul 2024
Alixia filed a Form D notice of exempt offering of securities showing a total offering amount of $3,465,450 and total amount sold of $1,825,445.
LinkedIn · Mar 2022
Olof Mollstedt announced Alixia's inclusion in Y Combinator Winter 2022 and described the company as developing cancer drugs by disrupting tumor-ecosystem interactions.
Jobs and careers at Alixia
0 jobs at Alixia
No open positions
Check back later for new openings